Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Clinical trial NCT02387125 · TERMINATED

Trial details

NCT number

NCT02387125

Sponsor

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Status

TERMINATED

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2015-02-28

Primary completion

2019-03-29

Enrollment

79

View on ClinicalTrials.gov